Assistant Professor of Medicine, University Tenn College of Medicine
Hematology
Dr. Furhan D. Yunus, MD
|
|
Give Review
Furhan Yunus practices Hematology. He graduated from King Edward Medical University. He has 3 awards "America's Top Doctors", "Memphis Magazine: Top Doctors" and "America's Top Doctors for Cancer". Furhan D. Yunus is a published physician. He published 20 publications, including: 'Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer.' He accepts Medicare.
Publications
- A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogeni...
- Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung Cancer.
- Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of Acute asthma.
- Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin''s Lymphoma.
- Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung Cancer.
- Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled Analysis of two randomized, controlled clinical trials.
- A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung Cancer (a Vanderbilt Cancer Ce...
- Weekly irinotecan and concurrent radiation therapy for stage III unresectable NSCLC.
- Weekly irinotecan and cisplatin in advanced non-small cell lung Cancer: a multicenter phase II study.
- Chronic myelogenous Leukemia. Clinical practice guidelines in oncology.
- Multiple myeloma.
- Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery.
- NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's Lymphomas.
- NCCN clinical practice guidelines in oncology: multiple myeloma.
- Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws.
- Non-Hodgkin''s Lymphomas.
- Multiple myeloma. Clinical practice guidelines in oncology.
- Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast Cancer.
- Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic Cancer.
Schools
King Edward Medical University
Meth Hospital
University Ariz College Med
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- America's Top Doctors
- Memphis Magazine: Top Doctors
- America's Top Doctors for Cancer
Education
-
University of Arizona -
King Edward Medical University
Hospital
-
University of Tennessee Medical Center
Drug Facts
| NPI NUMBER | 1326048356 | |
| NPPES Provider LastName | YUNUS | |
| NPPES Provider FirstName | FURHAN | |
| NPPES Provider ZIPCode | 38104 | |
| NPPES Provider State | TN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 2697.0 | |
| Distinct Opioid Count | 8.0 | |
| Opioid Claim Count | 597.0 | |
| Percent Opioid Claims | 22.14 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1326048356 |
| Last Name Of The Provider | YUNUS |
| First Name Of The Provider | FURHAN |
| View All |